Skip to Content
MilliporeSigma
All Photos(1)

Documents

SML2218

Sigma-Aldrich

SNS-032

≥98% (HPLC)

Synonym(s):

BMS-387032, N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H24N4O2S2
CAS Number:
345627-80-7
Molecular Weight:
380.53
MDL number:
MFCD09833875
UNSPSC Code:
12352200
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL

storage temp.

−20°C

SMILES string

O=C(NC1=NC=C(SCC2=NC=C(C(C)(C)C)O2)S1)C3CCNCC3

InChI

1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)

InChI key

OUSFTKFNBAZUKL-UHFFFAOYSA-N

Biochem/physiol Actions

SNS-032 (BMS-387032) is a selective and potent inhibitor of cyclin-dependent kinases (Cdks) 2, 7, and 9 that regulate the cell cycle and transcription. It has IC50 values of 38 nM for Cdk2, 62 nM for Cdk7, and 4 nM for Cdk9. SNS-032 was in clinical trials for a variety of cancers including chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rong Chen et al.
Blood, 113(19), 4637-4645 (2009-02-24)
Inhibitors of cyclin-dependent kinases (Cdks) have been reported to have activities in chronic lymphocytic leukemia cells by inhibiting Cdk7 and Cdk9, which control transcription. Here we studied the novel Cdk inhibitor SNS-032, which exhibits potent and selective inhibitory activity against
Calla M Olson et al.
Nature chemical biology, 14(2), 163-170 (2017-12-19)
Cyclin-dependent kinase 9 (CDK9), an important regulator of transcriptional elongation, is a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation. We characterized NVP-2, a selective ATP-competitive CDK9 inhibitor, and THAL-SNS-032, a selective CDK9 degrader consisting of
Daniela Cihalova et al.
Cancer chemotherapy and pharmacology, 76(1), 105-116 (2015-05-20)
ATP-binding cassette (ABC) transporters play an important role in multidrug resistance (MDR) toward anticancer drugs. Here, we evaluated interactions of cyclin-dependent kinase inhibitors (CDKi) AT-7519, flavopiridol and SNS-032 with the following ABC transporters in vitro: P-glycoprotein (ABCB1), breast cancer resistance

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service